779 related articles for article (PubMed ID: 21267586)
61. M1 macrophage recruitment correlates with worse outcome in SHH Medulloblastomas.
Lee C; Lee J; Choi SA; Kim SK; Wang KC; Park SH; Kim SH; Lee JY; Phi JH
BMC Cancer; 2018 May; 18(1):535. PubMed ID: 29739450
[TBL] [Abstract][Full Text] [Related]
62. Transcriptome analysis stratifies second-generation non-WNT/non-SHH medulloblastoma subgroups into clinically tractable subtypes.
Korshunov A; Okonechnikov K; Schrimpf D; Tonn S; Mynarek M; Koster J; Sievers P; Milde T; Sahm F; Jones DTW; von Deimling A; Pfister SM; Kool M
Acta Neuropathol; 2023 Jun; 145(6):829-842. PubMed ID: 37093271
[TBL] [Abstract][Full Text] [Related]
63. Comparison of Clinical and Molecular Wnt and SHH Subgroups in Medulloblastoma Tumor Cases.
Kaya IS; Aksoy S; Mutlu M; Tekin C; Taskapilioglu MO; Tunca B; Civan MN; Ocak PE; Kocaeli H; Bekar A; Egeli U; Cecener G; Tolunay S
Turk Neurosurg; 2021; 31(4):554-565. PubMed ID: 33978203
[TBL] [Abstract][Full Text] [Related]
64. β-Catenin-Gli1 interaction regulates proliferation and tumor growth in medulloblastoma.
Zinke J; Schneider FT; Harter PN; Thom S; Ziegler N; Toftgård R; Plate KH; Liebner S
Mol Cancer; 2015 Feb; 14(1):17. PubMed ID: 25645196
[TBL] [Abstract][Full Text] [Related]
65. Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma.
Park AK; Lee JY; Cheong H; Ramaswamy V; Park SH; Kool M; Phi JH; Choi SA; Cavalli F; Taylor MD; Kim SK
BMC Cancer; 2019 Jun; 19(1):571. PubMed ID: 31185958
[TBL] [Abstract][Full Text] [Related]
66. Nomograms based on preoperative multiparametric magnetic resonance imaging for prediction of molecular subgrouping in medulloblastoma: results from a radiogenomics study of 111 patients.
Dasgupta A; Gupta T; Pungavkar S; Shirsat N; Epari S; Chinnaswamy G; Mahajan A; Janu A; Moiyadi A; Kannan S; Krishnatry R; Sastri GJ; Jalali R
Neuro Oncol; 2019 Jan; 21(1):115-124. PubMed ID: 29846693
[TBL] [Abstract][Full Text] [Related]
67. GLI3 Is Associated With Neuronal Differentiation in SHH-Activated and WNT-Activated Medulloblastoma.
Natsumeda M; Miyahara H; Yoshimura J; Nakata S; Nozawa T; Ito J; Kanemaru Y; Watanabe J; Tsukamoto Y; Okada M; Oishi M; Hirato J; Wataya T; Ahsan S; Tateishi K; Yamamoto T; Rodriguez FJ; Takahashi H; Hovestadt V; Suva ML; Taylor MD; Eberhart CG; Fujii Y; Kakita A
J Neuropathol Exp Neurol; 2021 Jan; 80(2):129-136. PubMed ID: 33249504
[TBL] [Abstract][Full Text] [Related]
68. WNT/β-catenin pathway activation in Myc immortalised cerebellar progenitor cells inhibits neuronal differentiation and generates tumours resembling medulloblastoma.
Rogers HA; Sousa S; Salto C; Arenas E; Coyle B; Grundy RG
Br J Cancer; 2012 Sep; 107(7):1144-52. PubMed ID: 22929883
[TBL] [Abstract][Full Text] [Related]
69. Sonic hedgehog-associated medulloblastoma arising from the cochlear nuclei of the brainstem.
Grammel D; Warmuth-Metz M; von Bueren AO; Kool M; Pietsch T; Kretzschmar HA; Rowitch DH; Rutkowski S; Pfister SM; Schüller U
Acta Neuropathol; 2012 Apr; 123(4):601-14. PubMed ID: 22349907
[TBL] [Abstract][Full Text] [Related]
70. Medulloblastoma: Clinicopathological Correlates of SHH, WNT, and Non-WNT/SHH Molecular Subgroups Analysis and Prognostic Significance: Mono-Institutional Series.
Hasbay B; Kayaselcuk F; Suner HI; Sarialioglu F
Turk Neurosurg; 2022; 32(4):595-602. PubMed ID: 34751426
[TBL] [Abstract][Full Text] [Related]
71. p53 Function Is Compromised by Inhibitor 2 of Phosphatase 2A in Sonic Hedgehog Medulloblastoma.
Wei Y; Maximov V; Morrissy SA; Taylor MD; Pallas DC; Kenney AM
Mol Cancer Res; 2019 Jan; 17(1):186-198. PubMed ID: 30224541
[TBL] [Abstract][Full Text] [Related]
72. CTGF expression is indicative of better survival rates in patients with medulloblastoma.
Cruzeiro GAV; Lira RCP; de Almeida Magalhães T; Scrideli CA; Valera ET; Baumgartner M; Tone LG
Cancer Gene Ther; 2020 May; 27(5):378-382. PubMed ID: 31073205
[TBL] [Abstract][Full Text] [Related]
73. Inhibition of SHH pathway mechanisms by arsenic trioxide in pediatric medulloblastomas: a comprehensive literature review.
Klinger PH; Andrade AF; Delsin LE; Queiroz RG; Scrideli CA; Tone LG; Valera ET
Genet Mol Res; 2017 Feb; 16(1):. PubMed ID: 28218785
[TBL] [Abstract][Full Text] [Related]
74. Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort.
Pietsch T; Schmidt R; Remke M; Korshunov A; Hovestadt V; Jones DT; Felsberg J; Kaulich K; Goschzik T; Kool M; Northcott PA; von Hoff K; von Bueren AO; Friedrich C; Mynarek M; Skladny H; Fleischhack G; Taylor MD; Cremer F; Lichter P; Faldum A; Reifenberger G; Rutkowski S; Pfister SM
Acta Neuropathol; 2014 Jul; 128(1):137-49. PubMed ID: 24791927
[TBL] [Abstract][Full Text] [Related]
75. Desmoplastic/nodular medulloblastomas (DNMB) and medulloblastomas with extensive nodularity (MBEN) disclose similar epigenetic signatures but different transcriptional profiles.
Korshunov A; Sahm F; Okonechnikov K; Ryzhova M; Stichel D; Schrimpf D; Casalini B; Sievers P; Meyer J; Zheludkova O; Golanov A; Lichter P; Jones DTW; Pfister SM; Kool M; von Deimling A
Acta Neuropathol; 2019 Jun; 137(6):1003-1015. PubMed ID: 30826918
[TBL] [Abstract][Full Text] [Related]
76. WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma.
Zhukova N; Ramaswamy V; Remke M; Martin DC; Castelo-Branco P; Zhang CH; Fraser M; Tse K; Poon R; Shih DJ; Baskin B; Ray PN; Bouffet E; Dirks P; von Bueren AO; Pfaff E; Korshunov A; Jones DT; Northcott PA; Kool M; Pugh TJ; Pomeroy SL; Cho YJ; Pietsch T; Gessi M; Rutkowski S; Bognár L; Cho BK; Eberhart CG; Conter CF; Fouladi M; French PJ; Grajkowska WA; Gupta N; Hauser P; Jabado N; Vasiljevic A; Jung S; Kim SK; Klekner A; Kumabe T; Lach B; Leonard JR; Liau LM; Massimi L; Pollack IF; Ra YS; Rubin JB; Van Meir EG; Wang KC; Weiss WA; Zitterbart K; Bristow RG; Alman B; Hawkins CE; Malkin D; Clifford SC; Pfister SM; Taylor MD; Tabori U
Acta Neuropathol Commun; 2014 Dec; 2():174. PubMed ID: 25539912
[TBL] [Abstract][Full Text] [Related]
77. Medulloblastoma molecular dissection: the way toward targeted therapy.
Remke M; Ramaswamy V; Taylor MD
Curr Opin Oncol; 2013 Nov; 25(6):674-81. PubMed ID: 24076581
[TBL] [Abstract][Full Text] [Related]
78. Medulloblastoma: clinicopathological parameters, risk stratification, and survival analysis of immunohistochemically validated molecular subgroups.
Eid AM; Heabah NAE
J Egypt Natl Canc Inst; 2021 Feb; 33(1):6. PubMed ID: 33555447
[TBL] [Abstract][Full Text] [Related]
79. Medulloblastoma comprises four distinct molecular variants.
Northcott PA; Korshunov A; Witt H; Hielscher T; Eberhart CG; Mack S; Bouffet E; Clifford SC; Hawkins CE; French P; Rutka JT; Pfister S; Taylor MD
J Clin Oncol; 2011 Apr; 29(11):1408-14. PubMed ID: 20823417
[TBL] [Abstract][Full Text] [Related]
80. A simplified approach using Taqman low-density array for medulloblastoma subgrouping.
Cruzeiro GAV; Salomão KB; de Biagi CAO; Baumgartner M; Sturm D; Lira RCP; de Almeida Magalhães T; Baroni Milan M; da Silva Silveira V; Saggioro FP; de Oliveira RS; Dos Santos Klinger PH; Seidinger AL; Yunes JA; de Paula Queiroz RG; Oba-Shinjo SM; Scrideli CA; Nagahashi SMK; Tone LG; Valera ET
Acta Neuropathol Commun; 2019 Mar; 7(1):33. PubMed ID: 30832734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
